P161 Absolute bioavailability of glucosamine after administration of crystalline glucosamine sulfate in rats  by unknown
Osteoarthritis and Cartilage Vol. 13, Supplement A $83 
ankles was apparent and stood in contrast to higher magnitude 
and more focal exposures in the incongruous joints. 
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cumulative contact stress exposure per annum (MPa). 
Fractured ankles also exhibited correspondingly smaller area per- 
centages exposed to lower stresses. 
Conclusions: The present ankle cartilage stress data represent 
among the first successful applications of intra-articular contact 
FE analysis to a clinical series, on a patient-specific basis. Re- 
spective normal ankle instantaneous contact stress distributions 
at similar instants of the duty cycle, as well as cumulative whole- 
cycle contact stress exposures, showed expected individual vari- 
ations on common general patterns. Although preliminary in na- 
ture, the contact stress data from the normal ankles as a group 
differed appreciably from the situation prevailing for residual frac- 
ture incongruity. 
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RECONSTITUTION OF PROTEOGLYCANS IN HUMAN 
OSTEOARTHRITIC KNEE CARTILAGE AND ITS 
BIOMECHANICAL CONSEQUENCES 
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Aim of Study: Previous studies in our laboratory have demon- 
strated increases in glycosaminoglycans (GAG), proteoglycans 
(PG) and TGFI~ in articular cartilage and a delay of osteoarthri- 
tis (OA) progression in Hartley guinea pigs with exposure to cer- 
tain pulsed electromagnetic fields (PEMF). This study examines 
the effect of treatment with a specific PEMF upon PG synthesis, 
GAG content, and mechanical properties of human OA cartilage 
explants. 
Methods: 3mm human chondral cores were harvested from the 
lateral femoral condyle, lateral tibial plateau, and trochlea of 7 pa- 
tients undergoing total knee arthroplasty for treatment of OA with 
varus deformity. Mankin scoring was utilized to grade the histolog- 
ical severity of OA in each donor site. The chondral cores were 
cultured in DMEM and exposed to a specific PEMF for 1 h/day or 
4h/day for 14 days. Control groups were treated identically, but 
without PEMF exposure. [35S]-Sulfate incorporation, DNA quan- 
tification, and GAG content were deteremined by standard meth- 
ods. The aggregate modulus was determined with a confined 
compression test. 
Results: 1h/day PEMF treatment increased [35S]-Sulfate incor- 
poration in chondral cores harvested from the lateral femoral 
condyle and trochlea by 15.6% (p=0.0175) and 16.1% (p=0.0837) 
respectively when compared to control. No effect was observed 
in the lateral tibial plateau. 4h/day PEMF treatment decreased 
[35S]-Sulfate incorporation in lateral femoral condyle and tibial 
plateau by 10.5% (p=0.0354) and 17.15% (p=0.0329) respec- 
tively. No effect was observed in the trochlea. Stratification of 
the data by Mankin score demonstrated that chondral cores har- 
vested from sites with more severe OA (Mankin score > 6) re- 
sponded poorly to PEMF treatment. The tibial plateaus used in 
this study had Mankin scores > 6 suggesting that the lack of re- 
sponse in the 1 h/day treatment group was due to severity of OA 
rather than site specifity. GAG content increased by 35% (p=0.04) 
with 1h/day PEMF treatment. Aggregate modulus values were 
approximately 15% higher in the PEMF treated group. 
Conclusions: Stimulation of extracellular matrix (ECM) 
molecules can be achieved with certain configurations of dy- 
namic mechanical stress. Mechanical loads stimulate a number 
of strain-associated events, notably streaming potentials, which 
may act as secondary signaling phenomena. Electric currents 
can be induced in cartilage by externally applied electromagnetic 
fields without mechanical strain. Our data indicates that these 
fields induce a reconstitution of PG and GAG in human OA carti- 
lage together with an increase in aggregate modulus and there- 
fore can be said to be mechanomimetic. This occurs only in OA 
of mild severity and is related to exposure duration, frequency, 
and amplitude of the field. These results suggest a potential ther- 
apeutic application for this specific PEMF in the treatment of early 
OA. 
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GLUCOSAMINE SULFATE IN RATS 
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Aim of Study: Glucosamine pharmacokinetics has been recently 
described in humans after administration of the original crys- 
talline glucosamine sulfate preparation at therapeutic doses. This 
was possible thanks to the development and validation of an 
LC/MS/MS method with adequate sensitivity and specificity. Pre- 
vious animal studies with less sensitive methods and different 
glucosamine substances have suggested glucosamine absolute 
bioavailability to range between 6% and 21% The aim of the 
present study was to assess the absolute bioavailability of glu- 
cosamine after administration of crystalline glucosamine sulfate 
in the rat at pharmacologically relevant doses. 
Methods: Male Sprague-Dawley rats were treated with crys- 
talline glucosamine sulfate at the doses of 200 mg/kg by the oral 
and intravenous routes. This dose is similar to the human thera- 
peutic dose in osteoarthritis (1500 mg/day) as it corresponds to a 
human equivalent dose of 2000 mg for a 65 kg man. Plasma was 
collected before oral and intravenous administration and up to 
48 h from cannulated animals. Glucosamine plasma concentra- 
tions were determined by LC/MS/MS after extraction with trichloro 
acetic acid with a limit of quantitation of 2 ng/ml. 13C-labelled glu- 
cosamine was used as internal standard. The plasma concentra- 
tions were used for a non-compartmental pharmacokinetic anal- 
ysis. 
Results: The table below shows the results obtained. After oral 
administration of crystalline glucosamine sulfate at the dose of 
200 mg/kg, glucosamine is rapidly absorbed (Tmax = 0.25 h) 
and is available to the systemic circulation in rats. The absolute 
bioavailability is approximately 27%. After both oral and intra- 
venous administration unchanged glucosamine was detected in 
Mean (SD) pharmacokinetic parameters of glucosamine after oral and 
intravenous administration of crystalline glucosamine sulfate at the dose of 
200 mg/kg (n=3 for each administration route) 
Administration Route 
Parameter Oral Intravenous 
Cmax (ng/ml) 1057.8±771.5 2108.9±28.5 
AUCt (ng.h/ml) 1034.2±172.6 3957.7±589.3 
F (%) 26.6 - 
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plasma up to 48 h after dosing and the estimation of the elimina- 
tion half-life from plasma indicated that this parameter averages 
up to 15 hours. 
A visual inspection of the plasma concentration vs time profiles 
after oral and intravenous administration indicated that the elim- 
ination phase of glucosamine is similar after both administra- 
tion routes and thus that the absorption process of glucosamine 
through the gastrointestinal tract does not influence the drug dis- 
position. 
Conclusions: Oral administration of crystalline glucosamine sul- 
fate in the rat affords rapid and unlimited absorption of glu- 
cosamine supporting the validity of this administration route to 
obtain complete pre-systemic availability. The absolute bioavail- 
ability is in the 30% range and the pharmacokinetic pattern after 
oral administration resembles the recent human findings. 
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CLINICAL EFFECTIVENESS AND DOSE RESPONSE OF 
IMAGE-GUIDED INTRA-ARTICULAR CORTICOSTEROID 
INJECTIONS FOR HIP OSTEOARTHRITIS 
PG Conaghan 1 , AM Keenan 1 , P Robinson 2 
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Aim of Study: To assess symptomatic hange after fluoroscop- 
ically guided intra-articular corticosteroid (lAST) injection in hip 
osteoarthritis (OA), and to examine dose-response and predic- 
tors of response. 
Methods: After institutional ethics approval, 120 consecutive OA 
hip patients (90 women, 30 men, median age 64 years) referred 
for lAST injection were prospectively included. Body mass index 
(BMI), WOMAC scores, conventional radiographic grade (Kell- 
gren and Lawrence scoring) and ultrasound capsular thickness 
(graded normal, mild, moderate and severe) were recorded at 
baseline. All injections were performed fluoroscopically using 40 
mg (n=75) or 80mg (n=45) of methylprednisolone and 4cc of 
0.5% bupivocaine. Repeat WOMAC scores were obtained 6 and 
12 weeks after injection. Analyses were performed on percentage 
change from baseline for WOMAC scores, with clinical 'respon- 
ders' classified as those achieving greater than 15% reduction in 
baseline pain score. 
Results: There was significant pain improvement for 40mg and 
80mg doses at 6 weeks (Z=-3.895, p<0.001 ;Z=-4.323, p<0.001 )
but only for the 80mg dose at week 12 (Z=3.164, p=0.002). Both 
the 40 and the 80mg doses demonstrated a significant stiffness 
improvement at 6 weeks (C2=14.469, df=2, p=0.001; c2=29.457, 
df=2, p<0.001), but only the 80mg dose maintained this effect at 
week 12. Only the 80mg dose showed a significant improvement 
in disability over 12 weeks (Z=-2.877, p=0.004). Clinically impor- 
tant improvement (>15%) only occurred with the 80mg dose at 
6 weeks for pain (27%), stiffness (25%) and disability (19.25%). 
Imaging findings did not relate to severity of symptoms or re- 
sponse. Lower BMI was the only predictor of response. 
Conclusion: This prospective study demonstrates for the first 
time a dose-response to lAST, with methylprednisolone 80mg 
providing a significant improvement in pain, stiffness and function 
in a large OA hip cohort. However, clinically important improve- 
ment was only evident at 6 weeks post-injection. 
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EFFECT OF LONG TERM ORAL ADMINISTRATION OF 
GLUCOSAMINE HYDROCHLORIDE AND CHONDROITIN 
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DEGENERATION IN A GUINEA PIG MODEL OF 
SPONTANEOUS OSTEOARTHRITIS 
T Sumino, J Ryu, M Seki, T Kudo 
Department of Orthopaedic Surgery, Nihon Universi~ School of 
Medicine, Itabashi-ku, Tokyo-to, Japan; Department of 
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Nihon Universi~ School of Medicine, Itabashi-ku, Tokyo-to, 
Japan; Department of Orthopaedic Surgeryrsity, Nihon 
University, School of Medicine, Itabashi-ku, Tokyo-to, Japan 
Objective: Glucosamine hydrochloride (glucosamine) and chon- 
droitin sulfate (CS) are commonly used as supplemental drugs 
for treatment of osteoarthritis (OA) and are shown to modify the 
progression and symptom of OA in clinical trials. We investigated 
the effect of long term oral administration of glucosamine and CS 
on cartilage degeneration in a guinea pig model of spontaneous 
OA. 
Methods: Glucosamine (150mg/kg) or CS (150mg/kg)-contain- 
ing foods were given to the guinea pigs for total of 12 months. The 
effects of glucosamine and CS on the knee cartilage degenera- 
tion were examined by evaluating radiographs (osteophyte forma- 
tion and osteosclerotic hanges), serum concentration of CS6S, 
CS4S, and histology compared to the controls at 3, 6, 12 months. 
Histological changes were evaluated by Modified Mankin's grad- 
ing system scored by structure, cellular abnormality and matrix 
staining. Matrix metalloproteinase III (MMP-III) staining was per- 
formed using immunohistochemistry. 
Results: There was no difference in the radiographical OA 
changes in all three groups. In biochemical analysis, there was 
no difference in the serum concentration of CS6S, CS4S and 
in the 6S/4S ratio. In contrast, there was a significant decrease 
in the score of matrix staining at 12 months in the glucosamine 
group and CS group compared to that in the control (p<0.0015, 
p<0.001). MMP-III expression was equally seen in the cartilage 
cells in all three groups and was expanded into the inner layer 
with progression of OA, being maximum at 6 months. 
Conclusion: Our results indicate that long term oral administra- 
tion of glucosamine or CS can inhibit the release and destruction 
of extracelluar matrix in the cartilage of OA by a mechanism inde- 
pendent of MMP-III expression. These results provide suggestive 
mechanism to explain the beneficial effect of glucosamine and CS 
in the prevention of articular cartilage loss in patients with OA. 
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CHARACTERISTICS OF PATIENTS WHO RESPOND TO 
PLACEBO IN THE GLUCOSAMINE/CHONDROITIN 
ARTHRITIS INTERVENTION TRIAL (GAIT) 
H Shi 1 , DJ Reda 1 , DO Clegg 2, the GAIT Investigators 
1 Coop Studies Program, Veterans Affairs, Hines, IL; 2School of 
Medicine, University of Utah, Salt Lake Ci~ UT 
GAIT was a randomized double-blind placebo- and celecoxib- 
controlled trial of 1583 osteoarthritis (OA) patients designed to 
evaluate the efficacy of glucosamine, chondroitin sulfate, and 
the combination in improving OA knee pain. The primary out- 
come was defined as the proportion of patients who achieved 
a 20% improvement in the Western Ontario and McMaster Uni- 
versity Osteoarthritis Index (WOMAC) summed pain subscale 
at the end of the treatment compared to baseline. A 60.1% 
placebo response rate was observed. Table 1 compares selected 
baseline characteristics between placebo responders and non- 
responders. 
